| 摘要: |
| ［摘要］ IgA肾病（IgAN）是全球最常见的原发性肾小球疾病，亚太地区疾病负担较重。该疾病预后异质性大，30%～40%的患者20～30年内可进展至终末期肾病。由于发病机制尚未完全明确，IgAN治疗仍面临挑战，传统治疗的局限性使得许多患者治疗需求未能得到满足。该文对IgAN新支持治疗策略研究进展作一综述。 |
| 关键词: IgA肾病 支持治疗 蛋白尿 药物 |
| DOI：10.3969/j.issn.1674-3806.2026.08.19 |
| 分类号:R 692.31 |
| 基金项目:国家自然科学基金项目（编号：82270752、82470741）；湖南创新省份建设专项任务（编号：2025JJ30042） |
|
| Research progress in novel supportive treatment strategies for IgA nephropathy |
|
Yu Jianglong, Tang Xunzi, Liu Hong
|
|
Department of Cardiology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
|
| Abstract: |
| ［Abstract］ IgA nephropathy(IgAN) is the most common primary glomerular disease worldwide, with a particularly heavy disease burden in the Asia-Pacific region. The prognosis of the disease is highly heterogeneous, with 30%-40% of the patients progressing to end-stage renal disease within 20 to 30 years. Due to the incomplete understanding of its pathogenesis, the treatment of IgAN remains challenging, and the limitations of traditional therapies leave many patients with unmet treatment needs. In this paper, the research progress in novel supportive treatment strategies for IgAN is reviewed. |
| Key words: IgA nephropathy(IgAN) supportive treatment proteinuria drugs |
